Press Release

Proteon Therapeutics to Present at the Stifel 2018 Healthcare Conference November 13th

November 8, 2018 at 7:45 AM EST

WALTHAM, Mass., Nov. 08, 2018 (GLOBE NEWSWIRE) -- Proteon Therapeutics, Inc. (Nasdaq: PRTO), a company developing novel, first-in-class therapeutics to address the medical needs of patients with kidney and vascular diseases, today announced that Company management will present at the Stifel 2018 Healthcare Conference in New York, NY on Tuesday, November 13, 2018 at 5:00 p.m. ET.

A live audio webcast of the presentation can be accessed by visiting the Investor and Media section of the Company’s website at  A replay of the webcast will be archived on the Proteon website following the presentation. 

About Proteon Therapeutics

Proteon Therapeutics is committed to improving the health of patients with kidney and vascular diseases through the development of novel, first-in-class therapeutics. Proteon's lead product candidate, vonapanitase, is an investigational drug intended to improve hemodialysis vascular access outcomes. Proteon has completed enrollment in PATENCY-2, a Phase 3 clinical trial evaluating vonapanitase in patients with chronic kidney disease undergoing surgical creation of a radiocephalic arteriovenous fistula for hemodialysis. Proteon is also evaluating vonapanitase in a Phase 1 clinical trial in patients with peripheral artery disease. For more information, please visit

Investor Contact
George Eldridge, Proteon Therapeutics, Senior Vice President and Chief Financial Officer

Media Contact
Ann Stanesa, Ten Bridge Communications

New Proteon Logo - full color RGB.jpg

Source: Proteon Therapeutics, Inc.